Drug Information

Drug General Information
Drug ID
D08BJR
Former ID
DIB020136
Drug Name
Ki-20227
Synonyms
Ki 20227; Ki20227
Drug Type
Small molecular drug
Indication Discovery agent Investigative [528535]
Structure
Download
2D MOL
Formula
C24H24N4O5S
InChI
InChI=1S/C24H24N4O5S/c1-14(23-26-9-10-34-23)27-24(29)28-17-6-5-15(11-20(17)30-2)33-19-7-8-25-18-13-22(32-4)21(31-3)12-16(18)19/h5-14H,1-4H3,(H2,27,28,29)
InChIKey
SHPFDGWALWEPGS-UHFFFAOYSA-N
PubChem Compound ID
9869779
PubChem Substance ID
14834765, 24160801, 45292043, 80815482, 125329931, 125571010, 135685332, 135685333, 135685352, 136931825, 136959518, 137276037, 137875917, 139382726, 143499037, 152043707, 152234893, 152258204, 152344435, 160647040, 162205105, 172919149, 174561047, 178102317, 185998802, 189614654, 224053637, 230399915, 244672854, 252158098, 252215641, 252543319
Target and Pathway
Target(s) Mast/stem cell growth factor receptor Target Info Inhibitor [528535]
Vascular endothelial growth factor receptor 2 Target Info Inhibitor [528535]
mRNA of Colony stimulating factor-1 receptor Target Info Inhibitor [531679]
Beta platelet-derived growth factor receptor Target Info Inhibitor [528535]
KEGG Pathway Ras signaling pathway
Rap1 signaling pathway
Cytokine-cytokine receptor interaction
Endocytosis
PI3K-Akt signaling pathway
Hematopoietic cell lineage
Melanogenesis
Pathways in cancer
Acute myeloid leukemia
Central carbon metabolism in cancerhsa04014:Ras signaling pathway
VEGF signaling pathway
Focal adhesion
Proteoglycans in cancerhsa04010:MAPK signaling pathway
Calcium signaling pathway
Gap junction
Regulation of actin cytoskeleton
HTLV-I infection
MicroRNAs in cancer
Glioma
Prostate cancer
Melanoma
Central carbon metabolism in cancer
Choline metabolism in cancer
NetPath Pathway IL3 Signaling Pathway
IL4 Signaling Pathway
KitReceptor Signaling PathwayNetPath_14:IL2 Signaling PathwayNetPath_11:TCR Signaling Pathway
Notch Signaling Pathway
PANTHER Pathway Angiogenesis
VEGF signaling pathwayP00005:Angiogenesis
PDGF signaling pathway
Pathway Interaction Database C-MYB transcription factor network
Signaling events mediated by Stem cell factor receptor (c-Kit)hif2pathway:HIF-2-alpha transcription factor network
Beta3 integrin cell surface interactions
Signaling events mediated by TCPTP
SHP2 signaling
S1P1 pathway
VEGF and VEGFR signaling network
Integrins in angiogenesis
Signaling events mediated by VEGFR1 and VEGFR2
Notch-mediated HES/HEY networkptp1bpathway:Signaling events mediated by PTP1B
C-MYB transcription factor networkptp1bpathway:Signaling events mediated by PTP1B
S1P3 pathway
Nectin adhesion pathway
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
PDGFR-beta signaling pathway
Validated targets of C-MYC transcriptional repression
PDGF receptor signaling network
Reactome PIP3 activates AKT signaling
Regulation of KIT signaling
Constitutive Signaling by Aberrant PI3K in Cancer
RAF/MAP kinase cascadeR-HSA-194306:Neurophilin interactions with VEGF and VEGFR
VEGF binds to VEGFR leading to receptor dimerization
Integrin cell surface interactions
EPHA-mediated growth cone collapse
VEGFA-VEGFR2 Pathway
VEGFR2 mediated cell proliferationR-HSA-1257604:PIP3 activates AKT signaling
RAF/MAP kinase cascade
WikiPathways Kit receptor signaling pathway
Differentiation Pathway
Signaling by SCF-KIT
PIP3 activates AKT signaling
Cardiac Progenitor Differentiation
miR-targeted genes in muscle cell - TarBase
miR-targeted genes in lymphocytes - TarBase
miR-targeted genes in epithelium - TarBaseWP306:Focal Adhesion
Nifedipine Activity
Signaling by VEGF
AngiogenesisWP51:Regulation of Actin Cytoskeleton
MAPK Signaling Pathway
Osteoblast Signaling
Focal Adhesion
PDGF Pathway
Signaling Pathways in Glioblastoma
Signaling by PDGF
References
Ref 528535A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43.
Ref 528535A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model. Mol Cancer Ther. 2006 Nov;5(11):2634-43.
Ref 531679Comprehensive analysis of kinase inhibitor selectivity. Nat Biotechnol. 2011 Oct 30;29(11):1046-51.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.